MJID — Stock Film
STOCK FILMSCENE 1/10MJID · $1.24
Stock Expert AI presents
MJID
Ping An Biomedical Co., Ltd
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Ping An Biomedical Co., Ltd. A quick introduction.

On the stock market since 2025, it operates in the world of heavy industry. It has 8 employees. Now — the numbers.

on the stock market since 2025
8 employees
$25.4M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales have been shrinking.

An average decline of 4% a year over the last 3 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$99.5M
2021
$114.5M
2022
$82.6M
2023
$87.6M
2024
In the vault right now:
$0
DEBT: $10.8M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
Growth has stalled4/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $87.6M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $1.3M against $87.6M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, MJID sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MJID is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film